Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Fact-checking 5 misleading claims about Helene relief efforts
Recommended
NC elections upended by Helene: Voting could be delayed, ballots might be lost. Here's what you need to know
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Zealand Pharma
< Previous
1
2
Next >
Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism
October 08, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide
October 08, 2024
From
Zealand Pharma
Via
GlobeNewswire
Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024
September 30, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th
September 13, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
September 12, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
September 09, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
August 22, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma Announces Financial Results for the First Half of 2024
August 15, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results
August 12, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma Appoints Eric Cox as Chief Commercial Officer
July 29, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion
June 25, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion
June 25, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion
June 25, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
June 20, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
June 07, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL
June 06, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency
May 31, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024
May 29, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide
May 23, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma Announces Financial Results for the First Quarter of 2024
May 16, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results
May 09, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference
March 01, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma Announces Financial Results for the Full Year 2023
February 27, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
February 26, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results
February 20, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
January 19, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
January 17, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma completes registration of capital increase
January 12, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC
January 10, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion
January 08, 2024
From
Zealand Pharma
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.